ArticleAmerican journal of translational research2025
Combining serum biomarkers and MRI radiomics to predict treatment outcome after thermal ablation in hepatocellular carcinoma.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Sublethal heat stress synergizes with the tumor microenvironment to drive recurrence of hepatocellular carcinoma after thermal ablation: mechanisms, molecular predictors, and targeted interventions.Cell biology and toxicology · 2026Review
- Spectral CT quantitative parameters for predicting complete ablation after radiofrequency ablation in liver tumors: a retrospective study.Frontiers in oncology · 2026Article
- Artificial Intelligence in Thermal Ablation: Current Applications and Future Directions in Microwave Technologies.Biomimetics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the predictive value of serum alpha - fetoprotein (AFP), lectin-reactive alpha-fetoprotein (AFP-L3), and multimodal magnetic resonance imaging (MRI) radiomics in forecasting therapeutic efficacy and prognosis following radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC).
methodsA retrospective analysis was conducted on HCC patients who underwent RFA between January 2019 and December 2023. Clinical and radiologic features of HCC were analyzed. A predictive model was developed using clinical data and radiomic features collected before surgery, with the goal of predicting prognosis after RFA. The predictive performance of the model was evaluated using AUC values in both training and validation cohorts.
resultsA total of 298 HCC patients were included in the study, divided into a good prognosis group (n=145) and a poor prognosis group (n=153). Serum AFP and AFP-L3 levels were significantly higher in the poor prognosis group (P=0.007 and P=0.02, respectively). Independent predictive factors included: AFP-L3 (95% CI -1.228, -1.1.61; P<0.001), AFP (95% CI 0.017, 0.036; P<0.001), intratumoral hemorrhage (95% CI 0.380, 0.581; P<0.001), peritumoral arterial tumor enhancement (95% CI 0.193, 0.534; P<0.001) and low signal intensity around liver and gallbladder tumors (95% CI 0.267, 0.489; P<0.001). The combined clinical-radiological-radiomics model demonstrated superior predictive performance, with AUC value of 0.897 in the training set and 0.841 in the validation set, outperforming individual models and sequences.
conclusionThe integrated clinical-radiological-radiomics model showed excellent predictive performance for the prognosis of HCC patients undergoing RFA, surpassing individual models. Key predictors included serum AFP, AFP-L3 levels, intratumoral hemorrhage, and peritumoral low signal intensity. This multimodal approach offers a promising tool for individualized prognostic assessment and improved clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.